Sponsor
ViiV Healthcare
Clinical research sponsor
Clinical trials
60 shownA Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentNCT07393659 · lead sponsor · 2026-07-21
RECRUITINGA Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedNCT07650916 · lead sponsor · 2026-06-25
RECRUITINGMass Balance and Absolute Oral Bioavailability of [14C]VH4524184NCT07636928 · lead sponsor · 2026-06-04
RECRUITINGA Study to Investigate the Safety and PK of VH4770359 in Healthy ParticipantsNCT07525544 · lead sponsor · 2026-05-14
RECRUITINGA Study to Investigate Cabotegravir for Neonates Exposed to HIV-1NCT07275606 · lead sponsor · 2026-04-15
RECRUITINGA Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546 · lead sponsor · 2026-02-11
RECRUITINGA Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIVNCT06724640 · lead sponsor · 2024-12-16
RECRUITINGFirst Time in Human Study of Long Acting VH4524184 FormulationsNCT06310551 · lead sponsor · 2024-03-21
RECRUITINGPharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsNCT05674656 · lead sponsor · 2023-07-06
RECRUITINGA Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsNCT05418868 · lead sponsor · 2022-06-14
RECRUITINGA Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIVNCT07822477 · lead sponsor · 2026-11-06
NOT_YET_RECRUITINGA Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)NCT07816250 · lead sponsor · 2026-10-19
NOT_YET_RECRUITINGA Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult ParticipantsNCT07818915 · lead sponsor · 2026-09-15
NOT_YET_RECRUITINGA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVNCT07053384 · lead sponsor · 2025-07-10
ACTIVE_NOT_RECRUITINGA Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy AdultsNCT07066722 · lead sponsor · 2025-07-07
COMPLETEDA Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIVNCT06970223 · lead sponsor · 2025-04-22
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsNCT06786520 · lead sponsor · 2025-01-17
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)NCT06741397 · lead sponsor · 2024-12-20
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1NCT06694805 · lead sponsor · 2024-12-02
ACTIVE_NOT_RECRUITINGA Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIVNCT06652958 · lead sponsor · 2024-10-02
ACTIVE_NOT_RECRUITINGVH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)NCT06533280 · lead sponsor · 2024-08-02
WITHDRAWNLong-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)NCT06134362 · lead sponsor · 2024-05-14
ACTIVE_NOT_RECRUITINGA Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy ParticipantsNCT06368986 · lead sponsor · 2024-04-17
COMPLETEDA Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female ParticipantsNCT06310616 · lead sponsor · 2024-03-06
COMPLETEDA Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05979311 · lead sponsor · 2024-02-21
ACTIVE_NOT_RECRUITINGVH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1NCT06214052 · lead sponsor · 2024-02-07
COMPLETEDA Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1NCT06061081 · lead sponsor · 2023-12-21
TERMINATEDA Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy ParticipantsNCT06168318 · lead sponsor · 2023-12-18
COMPLETEDProof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected AdultsNCT06039579 · lead sponsor · 2023-10-25
COMPLETEDA Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult ParticipantsNCT06033547 · lead sponsor · 2023-09-12
COMPLETEDA Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy AdultsNCT06012136 · lead sponsor · 2023-08-24
COMPLETEDA Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)NCT05996471 · lead sponsor · 2023-08-17
ACTIVE_NOT_RECRUITINGA Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAFNCT05911360 · lead sponsor · 2023-07-07
COMPLETEDA Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05917509 · lead sponsor · 2023-07-06
COMPLETEDA Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) FormulationNCT05776108 · lead sponsor · 2023-03-23
COMPLETEDA Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) ActivityNCT05631704 · lead sponsor · 2022-12-02
COMPLETEDStudy to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR StudyNCT05896748 · lead sponsor · 2022-11-08
COMPLETEDA Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesNCT05514509 · lead sponsor · 2022-10-28
COMPLETEDFirst-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy ParticipantsNCT05393271 · lead sponsor · 2022-10-03
COMPLETEDA Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United StatesNCT05374525 · lead sponsor · 2022-05-18
COMPLETEDA Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult ParticipantsNCT05291520 · lead sponsor · 2022-02-23
COMPLETEDFirst-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy ParticipantsNCT05163522 · lead sponsor · 2021-12-13
COMPLETEDStudy Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)NCT04982445 · lead sponsor · 2021-11-18
COMPLETEDA Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected ParticipantsNCT05896761 · lead sponsor · 2021-10-28
COMPLETEDA Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive AdultsNCT04900038 · lead sponsor · 2021-08-18
TERMINATEDA Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected AdultsNCT04871113 · lead sponsor · 2021-06-22
COMPLETEDA Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult ParticipantsNCT04827134 · lead sponsor · 2021-05-07
COMPLETEDA Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy ParticipantsNCT04857892 · lead sponsor · 2021-04-21
COMPLETEDLow-dose Fostemsavir Extended Release Relative Bioavailability StudyNCT04757974 · lead sponsor · 2021-03-05
COMPLETEDEvaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy AdultsNCT04425902 · lead sponsor · 2020-12-16
COMPLETEDA Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive AdultsNCT04493216 · lead sponsor · 2020-11-18
TERMINATEDA Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedNCT04542070 · lead sponsor · 2020-11-09
COMPLETEDEffect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of MoxifloxacinNCT04563845 · lead sponsor · 2020-11-09
COMPLETEDDrug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)NCT04630002 · lead sponsor · 2020-10-28
COMPLETEDA Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European CountriesNCT04399551 · lead sponsor · 2020-09-28
COMPLETEDPharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254NCT04507321 · lead sponsor · 2020-09-24
COMPLETEDPharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult ParticipantsNCT04371380 · lead sponsor · 2020-09-16
COMPLETEDGSK3739937 First-Time-In-Human (FTIH) Study in Healthy VolunteersNCT04493684 · lead sponsor · 2020-07-31
COMPLETEDStudy to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsNCT04484337 · lead sponsor · 2020-07-31
COMPLETEDA Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy ParticipantsNCT04263142 · lead sponsor · 2020-01-27
COMPLETEDSponsor roles
lead sponsor259
collaborator121
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.